Remarkable response to anti-PD-L1 blockade in relapsed and refractory metastatic malignant giant cell tumor of bone: a case report
PD-L1 blockade should be considered for MGCTB expressing PD-L1. Unfortunately, pembrolizumab was stopped, which likely allowed for tumor progression in this case.
Authors
- Gary K. Schwartz (ORCID: https://orcid.org/0000-0003-1813-5061)
- Zachary D. C. Burke (ORCID: https://orcid.org/0000-0001-9601-0956)
- Jessica Leng
- John D. Reith (ORCID: https://orcid.org/0000-0002-0542-3040)
- Jerry T. Wu
- Scott E. Kilpatrick (ORCID: https://orcid.org/0000-0002-6830-3142)
- Elizabeth C. Nowak (ORCID: https://orcid.org/0000-0001-8791-6166)
- Jarrell Imamura
Institutions
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- University School (US)
- Case Comprehensive Cancer Center
- Case Western Reserve University (US)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1080/1750743x.2025.2582518
- Primary Topic
- Bone Tumor Diagnosis and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00